ISSN: 2474-9230
Authors: Behery MA*
Individualization of ovarian stimulation protocol in the intracytoplasmic sperm injection allows gynecologists to treat and manage infertile females according to their unique physiognomies. Ideally this would increase the clinical pregnancy rate, lessen the iatrogenic hazards such as ovarian hyperstimulation syndrome, and decline the risk of cancellation of cycles. Anti- Müllerian hormone (AMH) emitted via the granulosa cells from small growing follicles in ovary, is a key player in preserving the “follicle pool”. The aim of this work is to explore whether AMH could be a predictive marker for the selection of the optimal ovarian stimulation protocol for cases that undergo intracytoplasmic sperm injection. This study was a retrospective study, that analyzed data from 1005 patients whose underwent intracytoplasmic sperm injection at a university ART unit from January 2017 to December 2020 where 3 groups were validated according to the level of AMH. group1, includes patients with serum AMH<1 ng/ml, group2, includes patients with AMH 1-3 ng/ml and group3 with AMH>3 ng/ml. Our results had shown that the long agonist protocol had the superlative outcome in all groups of the study. Serum AMH levels concentration correlated strongly with oocyte yield. AMH level should be determined before embarking on COS protocol. Surprisingly, our results revealed that long agonist protocol had the best outcome in all groups.
Keywords: AMH; ICSI; Controlled Ovarian Stimulation
